Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC/MS-based protein quantification method

Dawn P G Fitzpatrick, Jin Sam You, Kerry G. Bernis, Jean Pierre Wery, James R. Ludwig, Mu Wang

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Platinum-based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum-based chemotherapy remain unclear. In this study, we applied an LC/MS-based protein quantification method to examine the global protein expression of two pairs of ovarian cancer cell lines, A2780/A2780-CP (cisplatin-sensitive/ cisplatin-resistant) and 2008/2008-C13*5.25 (cisplatin-sensitive/ cisplatin-resistant). We identified and quantified over 2000 proteins from these cell lines and 760 proteins showed significant expression changes with a false discovery rate of less than 5% between paired groups. Based on the results we obtained, we suggest several potential pathways that may be involved in cisplatin resistance in human ovarian cancer. This study provides not only a new proteomic platform for large-scale quantitative protein analysis, but also important information for discovery of potential biomarkers of cisplatin resistance in ovarian cancer. Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.

Original languageEnglish
Pages (from-to)246-263
Number of pages18
JournalProteomics - Clinical Applications
Volume1
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Biomarkers
Ovarian Neoplasms
Cisplatin
Labels
Proteins
Chemotherapy
Platinum
Cells
Drug Therapy
Cell Line
Oncology
Therapeutics
Drug Resistance
Proteomics
Pharmaceutical Preparations

Keywords

  • Cisplatin resistance
  • Label-free quantitative analysis
  • Mass spectrometry
  • Ovarian cancer

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC/MS-based protein quantification method. / Fitzpatrick, Dawn P G; You, Jin Sam; Bernis, Kerry G.; Wery, Jean Pierre; Ludwig, James R.; Wang, Mu.

In: Proteomics - Clinical Applications, Vol. 1, No. 3, 03.2007, p. 246-263.

Research output: Contribution to journalArticle

Fitzpatrick, Dawn P G ; You, Jin Sam ; Bernis, Kerry G. ; Wery, Jean Pierre ; Ludwig, James R. ; Wang, Mu. / Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC/MS-based protein quantification method. In: Proteomics - Clinical Applications. 2007 ; Vol. 1, No. 3. pp. 246-263.
@article{62537e5b26834d6896b40a67a043d2ea,
title = "Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC/MS-based protein quantification method",
abstract = "Platinum-based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum-based chemotherapy remain unclear. In this study, we applied an LC/MS-based protein quantification method to examine the global protein expression of two pairs of ovarian cancer cell lines, A2780/A2780-CP (cisplatin-sensitive/ cisplatin-resistant) and 2008/2008-C13*5.25 (cisplatin-sensitive/ cisplatin-resistant). We identified and quantified over 2000 proteins from these cell lines and 760 proteins showed significant expression changes with a false discovery rate of less than 5{\%} between paired groups. Based on the results we obtained, we suggest several potential pathways that may be involved in cisplatin resistance in human ovarian cancer. This study provides not only a new proteomic platform for large-scale quantitative protein analysis, but also important information for discovery of potential biomarkers of cisplatin resistance in ovarian cancer. Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.",
keywords = "Cisplatin resistance, Label-free quantitative analysis, Mass spectrometry, Ovarian cancer",
author = "Fitzpatrick, {Dawn P G} and You, {Jin Sam} and Bernis, {Kerry G.} and Wery, {Jean Pierre} and Ludwig, {James R.} and Mu Wang",
year = "2007",
month = "3",
doi = "10.1002/prca.200600768",
language = "English",
volume = "1",
pages = "246--263",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "3",

}

TY - JOUR

T1 - Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC/MS-based protein quantification method

AU - Fitzpatrick, Dawn P G

AU - You, Jin Sam

AU - Bernis, Kerry G.

AU - Wery, Jean Pierre

AU - Ludwig, James R.

AU - Wang, Mu

PY - 2007/3

Y1 - 2007/3

N2 - Platinum-based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum-based chemotherapy remain unclear. In this study, we applied an LC/MS-based protein quantification method to examine the global protein expression of two pairs of ovarian cancer cell lines, A2780/A2780-CP (cisplatin-sensitive/ cisplatin-resistant) and 2008/2008-C13*5.25 (cisplatin-sensitive/ cisplatin-resistant). We identified and quantified over 2000 proteins from these cell lines and 760 proteins showed significant expression changes with a false discovery rate of less than 5% between paired groups. Based on the results we obtained, we suggest several potential pathways that may be involved in cisplatin resistance in human ovarian cancer. This study provides not only a new proteomic platform for large-scale quantitative protein analysis, but also important information for discovery of potential biomarkers of cisplatin resistance in ovarian cancer. Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.

AB - Platinum-based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum-based chemotherapy remain unclear. In this study, we applied an LC/MS-based protein quantification method to examine the global protein expression of two pairs of ovarian cancer cell lines, A2780/A2780-CP (cisplatin-sensitive/ cisplatin-resistant) and 2008/2008-C13*5.25 (cisplatin-sensitive/ cisplatin-resistant). We identified and quantified over 2000 proteins from these cell lines and 760 proteins showed significant expression changes with a false discovery rate of less than 5% between paired groups. Based on the results we obtained, we suggest several potential pathways that may be involved in cisplatin resistance in human ovarian cancer. This study provides not only a new proteomic platform for large-scale quantitative protein analysis, but also important information for discovery of potential biomarkers of cisplatin resistance in ovarian cancer. Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.

KW - Cisplatin resistance

KW - Label-free quantitative analysis

KW - Mass spectrometry

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=38149014778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149014778&partnerID=8YFLogxK

U2 - 10.1002/prca.200600768

DO - 10.1002/prca.200600768

M3 - Article

VL - 1

SP - 246

EP - 263

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 3

ER -